NCT06784726 - Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

April 10, 2028

Study Completion Date

April 11, 2033

Conditions

Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell LymphomaRecurrent Primary Mediastinal Large B-Cell LymphomaRecurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Grade 3b Follicular LymphomaRefractory High Grade B-Cell LymphomaRefractory Primary Mediastinal Large B-Cell LymphomaRefractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL

Odronextamab

Given IV

PROCEDURE

Biospecimen Collection

Undergo collection of blood and oral or rectal swab samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Undergo CAR-T cell therapy

PROCEDURE

Computed Tomography

Undergo PET/CT

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Biopsy

Undergo tissue biopsy

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University of Washington

OTHER